New daratumumab Phase 2 results posted in stage 3B AL amyloidosis; AFT-19 results still standingNov 13Weekly roundup, 5 itemsapalutamidedaratumumabUpdated
Pfizer raises 2026 guidance after Q3, reports pipeline progress and new CFONov 3Quarterly updateBioNTech SEC4 Therapeutics, Inc.
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
J&J reports Q3 2026 results, raises full-year sales and EPS guidanceOct 13Quarterly updateJohnson & Johnson
Kairos Pharma reports positive interim PFS data for ENV-105 in prostate cancer trialOct 6Clinical readoutKairos Pharma, LTD.
Monte Rosa reports Q2 2026 results as MGD pipeline advances on three frontsAug 6Quarterly updateMonte Rosa Therapeutics, Inc
Monte Rosa registers Phase 2 trial pairing MRT-2359 with apalutamide in prostate cancerAug 4Trial updateapalutamideMonte Rosa Therapeutics, Inc
FDA approves labeling supplement for Janssen's Erleada (apalutamide)Jun 29Regulatory decisionapalutamideJohnson & Johnson